Roivant Sciences (ROIV) Enterprise Value (2020 - 2026)

Roivant Sciences (ROIV) has 6 years of Enterprise Value data on file, last reported at -$1.1 billion in Q1 2026.

• Quarterly Enterprise Value rose 57.83% year-over-year to -$1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.1 billion (up 57.83% YoY) and the FY2026 annual result came in at -$1.1 billion, up 57.83% from the prior year.
• Enterprise Value climbed to -$1.1 billion in Q1 2026, from -$3.8 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$42.6 million in Q4 2024 to a low of -$6.4 billion in Q4 2023.
• A 5-year average of -$2.7 billion and a median of -$1.9 billion in 2024 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value surged 99.34% — and 2025, when it tumbled 8873.63%.
• Tracing ROIV's Enterprise Value over 5 years: stood at -$1.8 billion in 2022, then plunged by 258.08% to -$6.4 billion in 2023, then surged by 99.34% to -$42.6 million in 2024, then plunged by 8873.63% to -$3.8 billion in 2025, then jumped by 72.23% to -$1.1 billion in 2026.
• The last three Enterprise Value figures came in at -$1.1 billion (Q1 2026), -$3.8 billion (Q4 2025), and -$3.9 billion (Q3 2025), per Business Quant data.